Single-center study of COVID-19 in patients with chronic lymphocytic leukemia

To investigate the vaccination status, characteristics and prognosis of patients suffering from a combination of COVID-19 and chronic lymphocytic anemia (CLL) in China. Clinical data of 328 patients with chronic lymphocytic leukemia (CLL) who were first diagnosed with COVID-19 and treated in the Department of Hematology of Jiangsu Provincial People's Hospital between November 2022 and February 2023 were retrospectively analyzed. Univariate and multivariate analysis of data of patients with severe/critical COVID-19 were conducted by applying the binary logistic regression model. The median age of the CLL patients was 60 (24-87) years. 23.5% (77/328) of these patients suffered from severe/critical COVID-19 infection. Univariate analysis of the data demonstrated that a combination of factors including age >67 years ( =2.15, 95% 1.24- 3.73, =0.006), diabetes ( =2.09, 95% 1.05-4.20, =0.037), chronic hepatitis B ( =2.91, 95% 1.30-6.51, =0.010), CLL progressive ( =3.79, 95% 1.57-9.15, =0.003) and CD20 antibody-based